United Therapeutics Corporation share price logo

United Therapeutics Corporation Share Price

NASDAQ: UTHR

Large Cap

$459.27

+43.93

(+10.58%)

Live

as on

United Therapeutics Corporation Stock Performance

as on October 29, 2025 at 7:40 pm IST

  • Day's Low

    Day's High

    $421.68
    $468.03
    downward going graph

    8.18%

    Downside

    1.91%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $266.98
    $459.48
    downward going graph

    41.87%

    Downside

    0.05%

    Upside

    downward going graph

United Therapeutics Corporation share price movements today

Previous Close
$415.34
Open
$422.48
Volume
512.7K
Day's Low - High
$421.68 - $468.03
52 Week Low - High
$266.98 - $459.48

United Therapeutics Corporation Historical Returns

1 Month Return
-2.11 %
3 Month Return
+ 39.58 %
1 Year Return
+ 17.73 %
3 Year Return
+ 78.91 %
5 Year Return
0 %

United Therapeutics Corporation Stock Fundamentals & Key Indicators

Check United Therapeutics Corporation market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$18.8B

EPS (TTM)

26.6517

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.10%

PE Ratio (TTM)

16.2

Industry PE ratio

19.200384615384614

PEG Ratio

1.4347

EBITDA

1.6B

Revenue (TTM)

3.1B

Profit Margin

40.36%

Return On Equity TTM

19.30%

United Therapeutics Corporation Stock Valuation

Track how United Therapeutics Corporation P/E has moved over time to understand its valuation trends.

United Therapeutics Corporation in the last 5 years

  • Overview

  • Trends

Lowest (10.67x)

March 31, 2024

Today (16.20x)

October 29, 2025

Industry (19.20x)

October 29, 2025

Highest (19.96x)

September 30, 2021

LowHigh

Today’s Price to Earnings Ratio: 16.20x

United Therapeutics Corporation vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of United Therapeutics Corporation with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$18.8BNA16.240.36%
BUY$41.6BNA20.9113.81%
BUY$14.6B48.99%43.613.88%
BUY$65.4B-9.79%25.1327.83%

Stock Returns calculator for United Therapeutics Corporation Stock including INR - Dollar returns

The United Therapeutics Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

United Therapeutics Corporation investment value today

Current value as on today

₹1,35,240

Returns

₹35,240

(+35.24%)

Returns from United Therapeutics Corporation Stock

₹30,179 (+30.18%)

Dollar Returns*

₹5,061 (+5.06%)

Analyst Recommendation on United Therapeutics Corporation Stock

Based on 22 analysts

BUY

81.82%

Buy

13.64%

Hold

4.55%

Sell

Based on 22 analysts, 81.82% of analysts recommend a 'BUY' rating for United Therapeutics Corporation. Average target price of $492.85

United Therapeutics Corporation Share Price Target

Get share price movements and forecasts by analysts on United Therapeutics Corporation.

What analysts predicted

6.81%UPSIDE

Target Price

$492.85

Current Price

$459.27

Analyzed by

22 Analysts

Target

$492.85

United Therapeutics Corporation target price $492.85, a slight upside of 6.81% compared to current price of $459.27. According to 22 analysts rating.

United Therapeutics Corporation Stock’s Investor Sentiment and Interest

Search interest for United Therapeutics Corporation Stock has decreased by -73% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-73% versus previous 30 day period

United Therapeutics Corporation Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
506
596
609
614
677
714
748
735
794
798
Gross Profit
454
532
539
543
604
637
665
660
701
711
Operating Income
284
313
327
260
356
319
343
357
382
364
EBITDA
319
326
340
324
426
338
417
424
382
436
Interest Expense
13
14
15
15
13
11
10
7
6
7
Depreciation
13
12
13
13
15
18
19
19
19
21
Income Before Tax
291
335
351
295
398
355
388
396
423
408
Income Tax Expense
51
76
84
78
92
77
79
95
101
98
Net Income
240
259
267
217
306
278
309
301
322
309
Net Profit Margin
47.52%
43.45%
43.91%
35.32%
45.24%
38.90%
41.27%
40.94%
40.56%
38.76%

United Therapeutics Corporation Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
1,465
1,598
1,725
1,627
1,448
1,483
1,685
1,936
2,327
2,877
Gross Profit
1,396
1,526
1,619
1,429
1,331
1,375
1,563
1,789
2,070
2,567
Operating Income
699
1,061
814
805
-187
593
555
979
1,184
1,377
EBITDA
1,082
1,090
1,053
838
-74
646
736
1,040
1,386
1,654
Interest Expense
4
3
9
13
44
23
18
32
59
42
Depreciation
-
-
31
35
45
49
49
51
53
72
Income Before Tax
1,044
1,060
769
758
-165
638
593
950
1,274
1,539
Income Tax Expense
392
346
351
169
-60
124
118
223
289
343
Net Income
651
713
417
589
-104
514
475
727
984
1,195
Net Profit Margin
44.46%
44.64%
24.22%
36.20%
-7.21%
34.71%
28.23%
37.56%
42.31%
41.53%

United Therapeutics Corporation Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
259
267
217
306
278
309
301
322
309
Operating Cash Flow
106
346
150
376
232
377
341
461
191
Investing Cash Flow
-227
-313
42
735
-80
-114
-123
-164
-299
Financing Cash Flow
24
7
-92
-1,068
-48
-64
-74
-93
-198
Change in Cash
-96
40
100
43
104
198
143
202
-306

United Therapeutics Corporation Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
713
417
589
-104
514
475
727
984
1,195
Operating Cash Flow
643
474
778
-206
755
598
802
978
1,327
Investing Cash Flow
48
-835
-820
-335
-738
-486
-811
-719
417
Financing Cash Flow
-497
43
6
611
-16
44
75
-11
-1,254
Change in Cash
191
-317
-35
69
0
156
66
246
489

Global Institutional Holdings in United Therapeutics Corporation

Funds
Holdings
BlackRock Inc
11.79%
Vanguard Group Inc
9.84%
venBio Select Advisor LLC
5.24%
State Street Corp
4.79%
Renaissance Technologies Corp
4.69%

United Therapeutics Corporation News & Key Events

  • img

    Today's Timeline - 29 October

    Wed, 04:05 PM

    -

    United Therapeutics reports record Q3 2025 revenues of $799.5 million, driven by strong sales of Tyvaso and Orenitram.

    Wed, 04:18 PM

    -

    United Therapeutics misses revenue estimates but beats EPS expectations in Q3 2025, stock drops 2.4% post-results.

Insights on United Therapeutics Corporation

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, UTHR has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 735.9M → 798.6M (in $), with an average increase of 3.9% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, UTHR stock has moved up by 39.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Neurocrine Biosciences Inc. has given 26.8% return, outperforming this stock by 9.1%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 322.2M → 309.5M (in $), with an average decrease of 3.9% per quarter

About United Therapeutics Corporation

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
OrganisationUnited Therapeutics Corporation
Headquarters1000 Spring Street, Silver Spring, MD, United States, 20910
IndustryHealth Technology
CEODr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
E-voting on sharesClick here to vote

Key Management of United Therapeutics Corporation

Name

Title

Dr. Leigh Peterson

Executive Vice President of Product Development & Xenotransplantation

Mr. Gil Golden

Senior VP & Chief Medical Officer

Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.

Founder, Chairman & CEO

Mr. Michael I. Benkowitz

President & COO

Mr. Paul A. Mahon J.D.

Executive VP, General Counsel & Corporate Secretary

Harrison Silvers

Manager of Investor Relations

Kevin T. Gray

Senior Vice President of Strategic Operations & Logistics

Mr. Patrick Poisson

Executive VP of Technical Operations

Mr. James C. Edgemond

CFO & Treasurer

Ms. Holly Hobson

Associate Vice President of Human Resources

FAQs

What is United Therapeutics Corporation share price today?

United Therapeutics Corporation share price today is $459.27 as on . United Therapeutics Corporation share today touched a day high of $468.03 and a low of $421.68.

What is the 52 week high and 52 week low for United Therapeutics Corporation share?

United Therapeutics Corporation share touched a 52 week high of $459.48 on and a 52 week low of $266.98 on . United Therapeutics Corporation stock price today i.e. is trending at $459.27,which is 0.05% down from its 52 week high and 72.02% up from its 52 week low.

What is United Therapeutics Corporation's market capitalisation today?

United Therapeutics Corporation market capitalisation is $0.02T as on .

How to invest in United Therapeutics Corporation Stock (UTHR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for United Therapeutics Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in United Therapeutics Corporation Shares that will get you 0.0033 shares as per United Therapeutics Corporation share price of $459.27 per share as on October 29, 2025 at 7:40 pm IST.

What is the minimum amount required to buy United Therapeutics Corporation Stock (UTHR) from India?

Indian investors can start investing in United Therapeutics Corporation (UTHR) shares with as little as ₹88.178 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.78 in United Therapeutics Corporation stock (as per the Rupee-Dollar exchange rate as on ). Based on United Therapeutics Corporation share’s latest price of $459.27 as on October 29, 2025 at 7:40 pm IST, you will get 0.0218 shares of United Therapeutics Corporation. Learn more about fractional shares .